The FDA has approved Novartis’ Diovan HCT (valsartan/hydrochlorothiazide tablets) and Exforge (amlodipine/valsartan tablets) as first-line therapies for hypertension in patients likely to need ...

The FDA approval of Diovan HCT and Exforge for first-line use reinforces current US guideline recommendations to start appropriate patients on combination therapy. Research suggests that up to 80% ...

Teva Pharmaceutical Industries Limited ( TEVA) has launched its generic version of Novartis' ( NVS) Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the U.S. Exforge HCT is ...